-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target

Benzinga·09/15/2026 10:28:37
语音播报
HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral to Buy and announces $9 price target.